Anser ADA
Use
Anser ADA is designed to monitor the therapeutic levels of adalimumab (ADA) and antibodies-to-adalimumab (ATA) in patients. This information guides clinicians in optimizing biologic dosage to ensure effective treatment and patient safety.
Special Instructions
The test utilizes a drug-tolerant homogeneous mobility shift assay (HMSA) method validated against WHO standards for ADA measurements. It is suitable for detecting drug levels in the presence of detectable drug concentrations, overcoming limitations of solid-phase assays.
Limitations
The Anser ADA test is classified as a laboratory-developed test, which means it is not cleared or approved by the FDA. Its use is limited to clinical contexts defined by its validation under CLIA regulations.
Methodology
Immunoassay (HMSA)
Biomarkers
Result Turnaround Time
3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.0 mL
Minimum Volume
0.5 mL for Peds
Container
Serum Separator Tube or Red-Top Tube
Storage Instructions
Transport ambient or with a cold pack. Do not freeze.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |